ReviewEndocrine connections2026
The IGF signaling axis in thyroid cancer: biological complexity and therapeutic challenges.
Review in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulation of the insulin-like growth factor (IGF) axis plays an important role in thyroid cancer progression, dedifferentiation, and therapeutic resistance. While most differentiated thyroid cancers have favorable outcomes, a clinically significant subset develops aggressive behavior or becomes radioiodine (RAI) refractory, for which effective treatments remain limited. Aberrant activation of IGF ligands, IGF-1 receptor (IGF-1R), insulin receptor isoforms (especially IR-A), and IGF-binding proteins (IGFBPs) enhances oncogenic signaling through the PI3K/AKT and MAPK pathways and disrupts differentiation programs essential for iodine handling. Emerging evidence supports an IGF-2/IR-A-dominant autocrine circuit as a feature of aggressive and RAI-refractory disease, highlighting its potential relevance for biomarker-driven patient stratification. However, the clinical translation of IGF-axis targeting in thyroid cancer remains limited, and IGF-1R-directed monotherapies have shown only modest efficacy owing to signaling redundancy, adaptive resistance, metabolic toxicities, and the lack of validated predictive biomarkers for patient selection. Consequently, current translational efforts increasingly emphasize rational combination strategies, targeted delivery platforms, and molecular imaging approaches. This review summarizes key mechanistic and translational insights into IGF signaling in thyroid cancer and discusses how IGF-axis modulation may be integrated into precision oncology strategies for advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.